



PANVERA.003.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thomas J. Burke et al.
Application No. : 09/467,628
Filed : December 20, 1999
For : KINASE ACTIVITY MEASUREMENT USING
FLUORESCENCE POLARIZATION

#11
S.93
6/19/02

June 10, 2002
Cambridge, Massachusetts 02178

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97(c)

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants, through their attorney,
make of record the documents listed below. A completed substitute for Form PTO-1449B listing
all of the documents in alphabetical order is enclosed herewith.

U.S. Patent Documents:

Foreign Patent Documents:

Other Prior Art – Non Patent Literature Documents:

AUCOUTURIER, P. et al. Fluorescence Polarization Immunoassay of Estradiol.
Diag. Immunol, 1983, Vol. 1, pages 310-314
CHECOVICH, W. J. et al. Fluorescence Polarization – A New Tool for Cell and
Molecular Biology. Nature, 18 May 1995, Vol. 375, pages 254-256

09467628

06060001 500725

05/17/2002 TLBU11

180.00 CH

02 FC:JEL


MIKSICEK, R. J. et al. Studies Using Fluorescent Tetrahydrochrysene Estrogens for In Situ Visualization of the Estrogen Receptor in Living Cells. Molecular Endocrinology. 1995, Vol. 9, pages 592-604

This Information Disclosure Statement is being filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached substitute for Form PTO-1449B. Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed substitute for Form PTO-1449B duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Please charge any fees that may be due to Deposit Account No. 50-0725, as indicated on the accompanying Fee Transmittal Form.

Respectfully submitted,



Andrew S. Marks (Reg. No. 33,259)
Attorney for Applicants
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139
Tel: (617) 444-6692
Fax: (617) 444-6483